Thought leadership calls for deep knowledge and insight. Driven by PharmSource’s decades of experience and evidence-based analysis, here we share industry and market insights and actionable recommendations for both buyers and sellers of bio/pharmaceutical contract services.

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on AmpliPhi

AmpliPhi Biosciences raised $9.1 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know that they plan to use the proceeds to fund general corporate purposes, including…

Learn more

PMA Approvals for Medical Devices and Diagnostics

The Devices and Diagnostics edition of the PharmSource Lead Sheet focuses on high risk devices that require Premarket Approval (PMA) from the US FDA. If we take a look at data extracted from the FDA’s database and the PharmSource Lead Sheet database, we can observe…

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on ContraVir

ContraVir Pharmaceuticals plans to raise $12 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know that they plan to use the proceeds to fund R&D activities and ongoing clinical trials of its pipeline, which may include…

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on BioCryst

BioCryst Pharmaceuticals plans to raise $45 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know that they plan to use the proceeds for future clinical development of BCX7353, for continued development of…

Learn more

PharmSource Coverage of AACR 2017 Yields Valuable BD Info

At AACR 2017 we gathered all the latest news and early research data in the oncology field from researchers from around the world. There was so much to report that 55% of our pipeline leads for the Lead Sheet Drug Edition for the Week of April 6th were in the oncology field, with 70% of these…

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on Aldeyra

Aldeyra Therapeutics raised $10.5 million in a secondary public offering.

What new business opportunities are most likely to surface from this? We know that they plan to use the proceeds to support R&D activities, including…

Learn more